Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$355 Mln
P/E Ratio
--
P/B Ratio
4.21
Industry P/E
--
Debt to Equity
0.25
ROE
-0.31 %
ROCE
-23.92 %
Div. Yield
0 %
Book Value
1.75
EPS
-0.57
CFO
$-50.65 Mln
EBITDA
$-32.38 Mln
Net Profit
$-91.79 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Alpha Teknova Inc (TKNO)
| -18.20 | 31.09 | -28.41 | 294.80 | -16.42 | -- | -- |
|
BSE Sensex
| 2.61 | 3.71 | 5.78 | 8.89 | 11.76 | 20.11 | 11.35 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Alpha Teknova Inc (TKNO)
| 122.39 | -33.87 | -72.46 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 12.66 | 10,562.04 | 12.43 | 12.69 | |
| 72.81 | 10,050.19 | 97.07 | 2.52 | |
| 296.92 | 11,609.25 | 277.57 | 3.65 | |
| 117.67 | 14,455.82 | 41.45 | 5.44 |
Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary products include pre-poured... media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California. Address: 2451 Bert Dr., Hollister, CA, United States, 95023 Read more
President, CEO & Director
Mr. Stephen Gunstream
President, CEO & Director
Mr. Stephen Gunstream
Headquarters
Hollister, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Alpha Teknova Inc (TKNO) stood at $ 119 Mln as on 31-Dec-24
The share price of Alpha Teknova Inc (TKNO) is $6.83 (NASDAQ) as of 29-Apr-2025 12:42 EDT. Alpha Teknova Inc (TKNO) has given a return of -16.42% in the last 3 years.
Alpha Teknova Inc (TKNO) has a market capitalisation of $ 355 Mln as on 28-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Alpha Teknova Inc (TKNO) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Alpha Teknova Inc (TKNO) and enter the required number of quantities and click on buy to purchase the shares of Alpha Teknova Inc (TKNO).
Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary products include pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California. Address: 2451 Bert Dr., Hollister, CA, United States, 95023
The CEO & director of Mr. Stephen Gunstream. is Alpha Teknova Inc (TKNO), and CFO & Sr. VP is Mr. Stephen Gunstream.
There is no promoter pledging in Alpha Teknova Inc (TKNO).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,126
|
|
|
1,078
|
|
|
1,054
|
|
|
964
|
| Alpha Teknova Inc (TKNO) | Ratios |
|---|---|
|
Return on equity(%)
|
-31.02
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
-70.86
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Alpha Teknova Inc (TKNO) was $0 Mln.
$0.12
(
